Mieszko Czaplinski

Mr. Mieszko Czaplinski

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
LLLeszek Litzbarski
Leszek Litzbarski
MOMarek Olesz
Marek Olesz
GRGrzegorz Redlarski
Grzegorz Redlarski
PTPiotr Tojza
Piotr Tojza
Arkadiusz ZakArkadiusz Zak
Arkadiusz Zak
Mieszko CzaplinskiMieszko Czaplinski
Mieszko Czaplinski
The objective of this study is to assess the impact of low-frequency electromagnetic fields (LF EMFs) generated by power infrastructure on the nearby environment. Measurements of electric (E) and magnetic (H) field intensities were conducted around high-voltage power lines, transformer stations and facilities related to them. Numerical simulations were also performed to model the distribution of the field values around real buildings in close proximity to power delivery systems. Given the ongoing scientific debate regarding the effects of EMFs on living organisms, the current analysis was based on the existing standards—particularly ICNIRP 2010 guidelines, which set the maximum allowable E and magnetic induction (B) values at 5 kV/m and 200 μT, respectively. Stricter national regulations were also examined, such as Poland’s 1 kV/m E limit in residential areas and Belgium’s 10 μT limit for B. The results showed that while most cases complied with ICNIRP 2010 standards, certain stricter local regulations were exceeded. Specifically, 9 of 14 cases exceeded Poland’s E limits, and 8 failed to meet Belgium’s B requirements. Only in one place—a warehouse near 110 kV power lines (in a critical case)—the ICNIRP limit B was exceeded. These findings underscore the variability in regulatory standards and highlight the need for localized assessments of EMF exposure.

4 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Mieszko CzaplinskiMieszko Czaplinski
Mieszko Czaplinski
GRGrzegorz Redlarski
Grzegorz Redlarski
PKPaweł Kowalski
Paweł Kowalski
PTPiotr Tojza
Piotr Tojza
ASAdam Sikorski
Adam Sikorski
Arkadiusz ZakArkadiusz Zak
Arkadiusz Zak
This review summarises potential applications of artificial intelligence (AI) in histopathological diagnostics of leukemias reported in the available literature. It compares existing AI models focused on analysing image-based cellular morphology, trained on datasets of either blood smears or bone marrow slides. Key findings indicate a rising trend in research output and literature on that topic, with models achieving high accuracy rates — up to over 95% in leukemia detection and subtype classification. The implications suggest that AI can significantly enhance diagnostic precision, reduce subjectivity, and streamline workflows in hematopathology. Possible limitations and difficulties of introducing AI to routine diagnostics are also elaborated on. Overall, integrating AI into leukemia diagnostics holds promise for improving early detection, supporting clinical decision-making, and advancing treatment in haematological malignancies.

23 October 2025 in Electronics
Verified
Journal Article
Open access
PDF file
Mieszko CzaplinskiMieszko Czaplinski
Mieszko Czaplinski
GRGrzegorz Redlarski
Grzegorz Redlarski
PKPaweł Kowalski
Paweł Kowalski
PTPiotr Tojza
Piotr Tojza
ASAdam Sikorski
Adam Sikorski
Arkadiusz ZakArkadiusz Zak
Arkadiusz Zak
Artificial intelligence applications in histopathological diagnostics are rapidly expanding, with particular promise in complex hematological malignancies where diagnostic accuracy remains challenging and subjective. This study undertakes a scoping review to systematically map the extent of research on artificial intelligence applications in histopathological diagnostics of leukemias, examine geographic distribution and methodological approaches, and assess the current state of AI model performance and clinical readiness. A comprehensive search was conducted in the Scopus database covering publications from 2018 to 2025 (as of 12 July 2025), using five targeted search strategies combining AI, histopathology, and leukemia-related terms. Following a three-stage screening protocol, 418 publications were selected from an initial pool of over 75,000 records across multiple countries and research domains. The analysis revealed a marked increase in research output, peaking in 2024 with substantial contributions from India (26.3%), China (17.9%), USA (13.8%), and Saudi Arabia (11.1%). Among 43 documented datasets ranging from 80 to 42,386 images, studies predominantly utilized convolutional neural networks and deep learning approaches. AI models demonstrated high diagnostic accuracy, with 25 end-to-end models achieving an average accuracy of 97.72% compared to 96.34% for 20 classical machine learning approaches. Most studies focused on acute lymphoblastic leukemia detection and subtype classification using blood smear and bone marrow specimens. Despite promising diagnostic performance, significant gaps remain in clinical translation, standardization, and regulatory approval, with none of the reviewed AI systems currently FDA-approved for routine leukemia diagnostics. Future research should prioritize clinical validation studies, standardized datasets, and integration with existing diagnostic workflows to realize the potential of AI in hematopathological practice.

17 February 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
RCRoman Cemaga
Roman Cemaga
PHPatryk Hebda
Patryk Hebda
Mieszko CzaplinskiMieszko Czaplinski
Mieszko Czaplinski
ESEwa Szplit
Ewa Szplit
MPMikołaj Patalong
Mikołaj Patalong
MKMateusz Kubicki
Mateusz Kubicki
Background: Cancers remain a leading cause of mortality in a modern society, and their incidence is growing each year. The disease and its related therapies cause considerable side effects, functional deterioration, and reduce quality of life (QoL), all of which correlate with less favourable outcomes. Physical activity (PA) represents a cost-effective and non-invasive adjunct to the traditional therapy regimes, which can alleviate these negative effects and improve clinical outcomes Aim: The narrative review summarises current evidence about the role of PA in oncology. It provides a solid background in biochemical mechanisms involved in the modulation of cancer biology and evaluates its clinical significance by assessing psychological, physiological, cognitive, QoL and mortality rates Methods: We conducted a narrative review of the available literature on the role of physical activity in modulating physiological and functional parameters, as well as mortality, in cancer patients. We considered original studies, reviews, systematic reviews and meta-analyses. Results: Evidence indicates that PA is an effective tool in both the prevention and management of cancers. Patients who engage in PA have improved metabolic, immune and oxidative stress parameters, which provide clinical outcomes such as improved QoL, cognitive, psychological and physiological performance. This consequently leads to a better prevention of cancers and provides benefits in terms of overall survival Conclusions: PA is an effective strategy for enhancing clinical outcomes in the cancer population and should be considered as an additional approach integrated into clinical guidelines.

17 September 2026 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
MNMaciej Piotr Niedźwiecki
Maciej Piotr Niedźwiecki
MLMonika Lejman
Monika Lejman
Mieszko CzaplinskiMieszko Czaplinski
Mieszko Czaplinski
JSJanusz Springer
Janusz Springer
ASAnna Synakiewicz
Anna Synakiewicz
EWEliza Wasilewska
Eliza Wasilewska
Central nervous system (CNS) relapse remains a major cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL). Repeated isolated CNS relapse is particularly rare and associated with poor prognosis, while optimal therapeutic strategies remain insufficiently defined. Intensified CNS-directed therapy may improve disease control but is also associated with substantial long-term neurotoxicity and survivorship burden. We present the case of a boy with favorable-risk B-cell ALL who developed two isolated CNS relapses despite a good initial response to frontline therapy and absence of classical CNS relapse risk factors. The second relapse was associated with extensive meningeal involvement and optic nerve infiltration. The patient underwent intensive multimodal CNS-directed therapy, including repeated intrathecal chemotherapy, liposomal cytarabine administered according to the IntReALL 2010 protocol, cranial irradiation, and allogeneic hematopoietic stem cell transplantation (alloHSCT) from a matched sibling donor. Durable long-term remission was achieved despite the extremely unfavorable prognosis that is associated with a second isolated CNS relapse. A twenty-year follow-up extending into early adulthood revealed substantial late complications, including epilepsy, transient ischemic attack, optic nerve injury, endocrinopathies, obesity, secondary thyroid malignancy, neurocognitive difficulties, and depression requiring long-term psychiatric and psychological support. The present case illustrates the complex balance between effective CNS disease control and cumulative treatment-related neurotoxicity in pediatric ALL survivors. It also highlights the cumulative CNS injury and long-term survivorship burden that is associated with repeated CNS relapse and multimodal CNS-directed therapy.

14 March 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Mieszko CzaplinskiMieszko Czaplinski
Mieszko Czaplinski
GRGrzegorz Redlarski
Grzegorz Redlarski
MWMateusz Wieczorek
Mateusz Wieczorek
PKPaweł Kowalski
Paweł Kowalski
PTPiotr Tojza
Piotr Tojza
Arkadiusz ZakArkadiusz Zak
Arkadiusz Zak
Background: Artificial intelligence (AI) shows promising results in lymphoma detection, prediction, and classification. However, translating these findings into practice requires a rigorous assessment of potential biases, clinical utility, and further validation of research models. Objective: The goal of this study was to summarize existing studies on artificial intelligence models for the histopathological detection of lymphoma. Design: This study adhered to the PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines. A systematic search was conducted across three major databases (Scopus, PubMed, Web of Science) for English-language articles and reviews published between 2016 and 2025. Seven precise search queries were applied to identify relevant publications, accounting for variations in study modality, algorithmic architectures, and disease-specific terminology. Results: The search identified 612 records, of which 36 articles met the inclusion criteria. These studies presented 36 AI models, comprising 30 diagnostic and six prognostic applications, with Convolutional Neural Networks (CNNs) being the predominant architecture. Regarding data sources, 83% (30/36) of datasets utilized Hematoxylin and Eosin (H&E)-stained images, while the remainder relied on diverse modalities, including IHC-stained slides, bone marrow smears, and other tissue preparations. Studies predominantly utilized retrospective, private cohorts with sample sizes typically ranging from 50 to 400 patients; only a minority leveraged open-access repositories (e.g., Kaggle, TCGA). The primary application was slide-level multi-class classification, distinguishing between specific lymphoma subtypes and non-neoplastic controls. Beyond diagnosis, a subset of studies explored advanced prognostic tasks, such as predicting chemotherapy response and disease progression (e.g., in CLL), as well as automated biomarker quantification (c-MYC, BCL2, PD-L1). Reported diagnostic performance was generally high, with accuracy ranging from 60% to 100% (clustering around 90%) and AUC values spanning 0.70 to 0.99 (predominantly >0.90). Conclusions: While AI models demonstrate high diagnostic accuracy, their translation into practice is limited by unstandardized protocols, morphological complexity, and the “black box” nature of algorithms. Critical issues regarding data provenance, image noise, and lack of representativeness raise risks of systematic bias, hence the need for rigorous validation in diverse clinical environments.